BioSpace News Archive

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $60,000,000 of shares of its common stock.

Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8, 2020.

Nordson Corporation announced the recent appointments of Dr. John DeFord, executive vice president and chief technology officer of Becton, Dickinson and Company, and Ms. Jennifer Parmentier, vice president and president – Motion Systems Group for Parker Hannifin Corporation, to its board of directors.

National Health Investors, Inc. announced that it will fund a $22.2 million development loan to construct The Courtyard of Sussex, a 110-unit independent living, assisted living and memory care community in Sussex, WI.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00am ET on Monday, December 7, 2020 to discuss updated findings from the first-in-human trial of IMGN632, an antibody-drug conjugate targeting CD123,

A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with COVID-19

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need

Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the third quarter ended September 30, 2020, and provided an update on its corporate developments.

While the coronavirus pandemic brought unforeseen global challenges in 2020, the psychedelic renaissance repeatedly garnered historic victories.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 4,000,000 shares of its common stock by certain of its stockholders.